IDL Diagnostics AB (publ) (FRA:80R)

Market Cap	6.04M -41.8%
Revenue (ttm)	4.91M -7.5%
Net Income	-1.12M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0134
Previous Close	0.0170
Day's Range	0.0134 - 0.0134
52-Week Range	0.0134 - 0.0548
Beta	n/a
RSI	33.35
Earnings Date	Apr 22, 2026

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2000
• Employees: 20
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 80R

Financial Performance

In 2025, IDL Diagnostics AB's revenue was 53.11 million, a decrease of -7.54% compared to the previous year's 57.44 million. Losses were -12.15 million, -71.38% less than in 2024.

Financial numbers in SEK